Company Overview

Ind-Swift Limited, established in 1986 by the Jain, Mehta, and Munjal families, is a leading pharmaceutical manufacturing and marketing company headquartered in Chandigarh, India. The company is renowned for its strength in innovative pharmaceutical products. Ind-Swift operates as a publicly listed entity on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) under the stock symbol INDSWFTLTD.

It holds a significant position within the Indian pharmaceutical landscape, ranked 35th overall in the industry and serving as the second-largest drug manufacturer in North India. Ind-Swift has cultivated a robust global presence, extending its network across 45 countries, underscoring its commitment to addressing healthcare needs internationally.

Financial Performance and Market Position

As of July 22, 2025, Ind-Swift Limited (INDSWFTLTD) has a market capitalization of ₹95.55 Crore, according to the latest market data. The company's financial metrics provide insight into its current market standing, with a P/E (Price-to-Earnings) ratio of 0.34 and a P/B (Price-to-Book) ratio of -0.14.

For the financial year ending March 31, 2023, the company reported Total Operating Revenue of ₹410.96 Crore against Equity Capital of ₹10.83 Crore. More recent data indicates an operating revenue of ₹467.56 Crore on a trailing 12-month basis. However, the company has encountered profitability challenges, reporting a consolidated loss of ₹5.50 Crore on a total income of ₹122.78 Crore for the quarter ended 2024.

The stock has experienced considerable volatility over the past year. The 52-week high for Ind-Swift Ltd (INDSWFTLTD) was ₹34.70, and the 52-week low was ₹12. Performance across different timeframes shows mixed results: the Ind-Swift Ltd share price increased by 11.73% on the BSE over the last month but declined by 28.47% on the BSE over the last 12 months.

Manufacturing and Operations

Ind-Swift operates a strong manufacturing infrastructure comprising five multi-purpose, multi-location plants spread across Northern India. These facilities are designed and built to meet international standards, adhering to the current guidelines of MHRA, EU, and WHO. This stringent adherence to global regulatory standards ensures the company's capability to effectively serve both domestic and international markets.

The company possesses world-class expertise in finished dosage forms, Active Pharmaceutical Ingredients (APIs), and herbal products. Its extensive product portfolio includes therapeutic categories such as cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics, and anti-fungals. Ind-Swift's research and development efforts are powered by a talented team of research scientists, formulation experts, clinical development, and regulatory affairs professionals, all contributing to the company's innovation-driven approach.

In 2006, Ind-Swift established a dedicated export division, forming the Global Business Unit as a 100% export-oriented unit for finished dosage forms. This strategic initiative has enabled the company to capitalize on international market opportunities and establish itself as a reliable global pharmaceutical partner.

Key Financial Metrics

• Quarterly Performance (ended 2024): Total Income ₹122.78 Crore, Consolidated Loss ₹-5.50 Crore

• Financial Year 2022-23: Total Operating Revenue ₹410.96 Crore, Equity Capital ₹10.83 Crore

• Trailing 12-Month Revenue: ₹467.56 Crore

• Market Capitalization: ₹95.55 Crore (as of July 22, 2025)

• P/E Ratio: 0.34

• P/B Ratio: -0.14

• 52-Week High: ₹34.70

• 52-Week Low: ₹12.00

• Promoter Holding: 55.58% (as of Mar 2025)

Leadership and Corporate Structure

The company is guided by experienced leadership. S R Mehta serves as the Chairman, and Puneet Khurana is the Company Secretary of Ind-Swift Ltd. The promoter group includes G Munjal, S R Mehta, V R Mehta, Himanshu Jain, N R Munjal, Rishav Mehta, Subhash Chander Galhotra, Anoop Michra, and Jagvir Singh, who collectively steer the company's strategic direction.

Promoter holding in Ind-Swift Ltd remained stable at 55.58% as of March 2025, consistent with the 55.58% recorded in June 2024. This stable promoter stake signifies continued confidence from the founding stakeholders in the company's long-term prospects.

Ind-Swift's Corporate Identification Number (CIN) is L24230CH1986PLC006897, and its registration number is 006897. The company's auditing is managed by Jain & Associates. This robust corporate structure ensures proper governance and regulatory compliance as the company continues to pursue growth opportunities in both domestic and international pharmaceutical markets.

Industry Position and Peers

Ind-Swift Ltd (INDSWFTLTD) operates within the Health Care sector, specifically the Pharmaceuticals sub-sector. The company competes with several well-established pharmaceutical firms in the Indian market. Its key peers include Sun Pharmaceutical Industries Ltd, Divi's Laboratories Ltd, Torrent Pharmaceuticals Ltd, Cipla Ltd, Mankind Pharma Ltd, Dr Reddy's Laboratories Ltd, and Zydus Lifesciences Ltd.

The Indian pharmaceutical industry continues to experience robust growth, propelled by increasing healthcare awareness, an aging population, and expanding access to medical care. Ind-Swift's position within this competitive landscape reflects its strategic focus on quality manufacturing, adherence to regulatory compliance, and its expansive international market presence. The company's commitment to innovation and global standards positions it to benefit from the ongoing expansion of India's pharmaceutical sector.